Women in STEM with Delphine Guyon-Gellin
Drug Target Review
MARCH 26, 2024
DGG: At Osivax, we’re working on a new class of vaccines that target invariant parts of mutating viruses; this approach is disruptive and very different from conventional vaccines. DGG: Vaccines are experiencing a revolution in the post-COVID era with the emergence of mRNA technology.
Let's personalize your content